Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atenolol + hydrochlorothiazide + amlodipine + hydralazine is a combination of four antihypertensive agents, each with a distinct mechanism of action, used together to manage high blood pressure (hypertension) in patients who require multiple medications for adequate control. Atenolol is a beta-1 selective adrenergic receptor blocker that reduces heart rate and cardiac output. Hydrochlorothiazide is a thiazide diuretic that lowers blood pressure by promoting sodium and water excretion via the kidneys. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle, leading to vasodilation and reduced peripheral resistance. Hydralazine is a direct-acting vasodilator that primarily relaxes arteriolar smooth muscle, further decreasing systemic vascular resistance. This multi-drug regimen may be considered in resistant hypertension or when monotherapy or dual therapy does not achieve target blood pressure[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atenolol + hydrochlorothiazide + amlodipine + hydralazine.